TY - JOUR T1 - METABOLISM OF PROPIONYL ERYTHROMYCIN LAURYL SU LFATE JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 164 LP - 170 VL - 3 IS - 3 AU - PATRICK J. MURPHY AU - TERRY L. WILLIAMS AU - ROBERT E. McMAHON AU - ROSS E. CRABTREE AU - ANTHONY S. RIDOLFO Y1 - 1975/05/01 UR - http://dmd.aspetjournals.org/content/3/3/164.abstract N2 - The absorption. excretion. and metabolism of [1-14]lauryl sulfate as either the sodium or propionyl erythromycin salt has been studied in the rat and man. In the rat 88% of the radiolabel from propionyl erythromycin [1-14]lauryl sulfate was excreted in the urine in the 24-hr period following a single oral dose. More than 95% of the radiolabel was excreted as the metabolite butyric acid 4-sulfate. This metabolite was shown to be derived from carbons 1 -4 of the lauryl sulfate moiety. There was no evidence of sulfate cleavage in the rat. In man 5 1 -59% of the administered radioactivity was recovered in the urine. The major excretion product was butyric acid 4-sulfate accounting for approximately 95% of urinary radioactivity. The remainder was unchanged lauryl sulfate. A significant portion of the radiolabeled propionyl erythromycin lauryl sulfate was converted to 14C02 indicating that the sulfate linkage was cleaved. A minimum value of 9-16% of the dose was metabolized in this manner. Copyright © 1975 by The American Society for Pharmacology and Experimental Therapeutics ER -